ClinicalTrials.Veeva

Menu

Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers

A

Alios Biopharma

Status and phase

Completed
Phase 1

Conditions

Respiratory Syncytial Virus Infections

Treatments

Drug: Placebo
Drug: ALS-008176

Study type

Interventional

Funder types

Industry

Identifiers

NCT01906164
ALS-8176-501
2012-004894-14 (EudraCT Number)

Details and patient eligibility

About

This study will assess the safety, tolerability, and pharmacokinetics (PK) of orally administered ALS-008176 in healthy volunteers.

Enrollment

101 patients

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Male or female subjects, 18-55 years of age, in good health with screening laboratory values within limits specified by the protocol
  • Body mass index 18-30 kg/m2
  • Female subjects must be of non-childbearing potential; male subjects must be surgically sterile or practicing birth control

Exclusion criteria

  • Clinically significant or uncontrolled medical illness
  • Use, or anticipated use during conduct of the study, of concomitant medications

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

101 participants in 2 patient groups, including a placebo group

ALS-008176
Experimental group
Treatment:
Drug: ALS-008176
Placebo
Placebo Comparator group
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems